All In Biotech

Drug Trial Radar · NCT04620330

A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) and BRAF-Mutant (BRAF-MT) Non-Small Cell Lung Cancer (NSCLC) (RAMP 202)

Last checked: Nov 19, 2026Latest source record: Jan 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Dec 31, 2020

Primary completion

Aug 29, 2023

Study completion Dec 12, 2023

Sponsor

Lead sponsor
Verastem, Inc.Industry
Sponsor type
Industry
First posted
Nov 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation

Interventions

  • avutometinib (VS-6766)Drug

    Monotherapy

  • avutometinib (VS-6766) and DefactinibDrug

    Combination therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the optimal regimen, either avutometinib (VS-6766) monotherapy or avutometinib (VS-6766) in combination with defactinib, in KRAS-G12V NSCLCTime frame: From start of treatment to confirmation of response; 24 weeks
  2. To evaluate the initial efficacy of avutometinib (VS-6766) in combination with defactinib in BRAF-MT NSCLCTime frame: From start of treatment to confirmation of response; 24 weeks
  3. To determine efficacy in KRAS-other (non-G12V) NSCLCTime frame: From start of treatment to confirmation of response; 24 weeks
  4. To determine the efficacy of avutometinib (VS-6766) in combination with defactinib in BRAF-MT NSCLCTime frame: From start of treatment to confirmation of response; 24 weeks

Locations

45 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Medical Center-Duchossois Center for Advanced Medicine

    Chicago, Illinois

  • Illinois Cancer Specialists

    Niles, Illinois

  • Hematology/Oncology Clinic, LLP

    Baton Rouge, Louisiana

  • Maryland Oncology Hematology P.A

    Columbia, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Cancer Institute/Henry Ford Health System

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Northwell Health-Monter Cancer Center

    Lake Success, New York

  • Zangmeister Cancer Center

    Columbus, Ohio

  • Northwest Cancer Specialists, P.C.

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Univ. of Pittsburgh Med Center

    Pittsburgh, Pennsylvania

  • Chattanooga Oncology Hematology Assoc.

    Chattanooga, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology

    Dallas, Texas

  • Texas Oncology Ft Worth Cancer Center

    Fort Worth, Texas

  • Texas Oncology

    Grapevine, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Centre Leon Berard

    Lyon, France

  • Hopital Nord Marseille

    Marseille, France

  • Hopital Cochin

    Paris, France

  • Institute De Cancerologie De L'Ouest Site Paul Papin Oncologie Medicale

    Saint-Herblain, France

  • Cancerologie Gustave Roussy - Cancer Medicine

    Villejuif, France

  • Klinikum Chemnitz gGmbH

    Chemnitz, Germany

  • Universitatsklinkum Leipzig

    Leipzig, Germany

  • Evangelisches Klinkum Bethel

    Straße, Germany

  • Irccs, Irts

    Meldola, Italy

  • UOC di Oncologia Medica

    Parma, Italy

  • Centro Ricerche Cliniche di Verona

    Verona, Italy

  • Azienda Ospedaliera Universitaria

    Orbassano, Torino, Italy

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.